Literature DB >> 33669083

Phelan McDermid Syndrome: Multiple Sclerosis as a Rare but Treatable Cause for Regression-A Case Report.

Sarah Jesse1, Jan Philipp Delling2, Michael Schön2, Tobias M Boeckers2,3, Albert Ludolph1,3, Makbule Senel1.   

Abstract

Phelan McDermid syndrome (PMcD) is a neurogenetic disease associated with haploinsufficiency of the SHANK3 gene due to a spectrum of anomalies in the terminal region of the long arm of chromosome 22. SHANK3 is the abbreviation for SH3 domain and ankyrin repeat-containing protein, a gene that encodes for proteins of the postsynaptic density (PSD) of excitatory synapses. This PSD is relevant for the induction and plasticity of spine and synapse formation as a basis for learning processes and long-term potentiation. Individuals with PMcD present with intellectual disability, muscular hypotonia, and severely delayed or absent speech. Further neuropsychiatric manifestations cover symptoms of the autism spectrum, epilepsy, bipolar disorders, schizophrenia, and regression. Regression is one of the most feared syndromes by relatives of PMcD patients. Current scientific evidence indicates that the onset of regression is variable and affects language, motor skills, activities of daily living and cognition. In the case of regression, patients normally undergo further diagnostics to exclude treatable reasons such as complex-focal seizures or psychiatric comorbidities. Here, we report, for the first time, the case of a young female who developed progressive symptoms of regression and a dystonic-spastic hemiparesis that could be traced back to a comorbid multiple sclerosis and that improved after treatment with methylprednisolone.

Entities:  

Keywords:  Phelan McDermid syndrome; SHANK3; autoimmune diseases; genetic autism spectrum; multiple sclerosis; regression

Mesh:

Substances:

Year:  2021        PMID: 33669083      PMCID: PMC7956287          DOI: 10.3390/ijms22052311

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  12 in total

1.  Expression of postsynaptic density proteins of the ProSAP/Shank family in the thymus.

Authors:  Peter Redecker; Jürgen Bockmann; Tobias M Böckers
Journal:  Histochem Cell Biol       Date:  2006-06-07       Impact factor: 4.304

2.  Prospective longitudinal overnight video-EEG evaluation in Phelan-McDermid Syndrome.

Authors:  Omar I Khan; Xiangping Zhou; Jill Leon; Riley Kessler; Thomas Gaughan; Precilla D'Souza; Andrea Gropman; Ninette Cohen; Owen Rennert; Ashura Buckley; Sara Inati; Audrey Thurm
Journal:  Epilepsy Behav       Date:  2018-02-03       Impact factor: 2.937

3.  A longitudinal perspective on the pharmacotherapy of 24 adult patients with Phelan McDermid syndrome.

Authors:  Willem M A Verhoeven; Jos I M Egger; Nicole de Leeuw
Journal:  Eur J Med Genet       Date:  2019-08-27       Impact factor: 2.708

Review 4.  Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.

Authors:  Alan J Thompson; Brenda L Banwell; Frederik Barkhof; William M Carroll; Timothy Coetzee; Giancarlo Comi; Jorge Correale; Franz Fazekas; Massimo Filippi; Mark S Freedman; Kazuo Fujihara; Steven L Galetta; Hans Peter Hartung; Ludwig Kappos; Fred D Lublin; Ruth Ann Marrie; Aaron E Miller; David H Miller; Xavier Montalban; Ellen M Mowry; Per Soelberg Sorensen; Mar Tintoré; Anthony L Traboulsee; Maria Trojano; Bernard M J Uitdehaag; Sandra Vukusic; Emmanuelle Waubant; Brian G Weinshenker; Stephen C Reingold; Jeffrey A Cohen
Journal:  Lancet Neurol       Date:  2017-12-21       Impact factor: 44.182

Review 5.  Growth factors and myelin regeneration in multiple sclerosis.

Authors:  H D Webster
Journal:  Mult Scler       Date:  1997-04       Impact factor: 6.312

Review 6.  Framework for assessing individuals with rare genetic disorders associated with profound intellectual and multiple disabilities (PIMD): the example of Phelan McDermid Syndrome.

Authors:  Latha Soorya; Jill Leon; M Pilar Trelles; Audrey Thurm
Journal:  Clin Neuropsychol       Date:  2017-12-21       Impact factor: 3.535

7.  Co-occurrence of Metachromatic Leukodystrophy in Phelan-McDermid Syndrome.

Authors:  Dararat Mingbunjerdsuk; Melissa Wong; Xiuhua Bozarth; Angela Sun
Journal:  J Child Neurol       Date:  2020-09-29       Impact factor: 1.987

8.  A pilot controlled trial of insulin-like growth factor-1 in children with Phelan-McDermid syndrome.

Authors:  Alexander Kolevzon; Lauren Bush; A Ting Wang; Danielle Halpern; Yitzchak Frank; David Grodberg; Robert Rapaport; Teresa Tavassoli; William Chaplin; Latha Soorya; Joseph D Buxbaum
Journal:  Mol Autism       Date:  2014-12-12       Impact factor: 7.509

9.  Insulin-like growth factor-1 stimulates regulatory T cells and suppresses autoimmune disease.

Authors:  Daniel Bilbao; Luisa Luciani; Bjarki Johannesson; Agnieszka Piszczek; Nadia Rosenthal
Journal:  EMBO Mol Med       Date:  2014-11       Impact factor: 12.137

10.  Neuropsychiatric decompensation in adolescents and adults with Phelan-McDermid syndrome: a systematic review of the literature.

Authors:  Alexander Kolevzon; Elsa Delaby; Elizabeth Berry-Kravis; Joseph D Buxbaum; Catalina Betancur
Journal:  Mol Autism       Date:  2019-12-24       Impact factor: 7.509

View more
  2 in total

1.  Molecular Research in Multiple Sclerosis.

Authors:  Maurine Fucito; Damiana Pieragostino
Journal:  Int J Mol Sci       Date:  2022-03-03       Impact factor: 5.923

2.  Phelan-McDermid Syndrome in Pediatric Patients With Novel Mutations: Genetic and Phenotypic Analyses.

Authors:  Liang Chen; Zhi-Ye Yao; Xiangtao Wu; Shao-Ru He; Yu-Mei Liu; Xue-Yan Wang; De-Zhi Cao; Xing-Kun Yang; Jian-Bo Zhao; Zi Ren; Hong Li; Zheng Pei; Hong-Ke Ding; Zhi-Chun Feng
Journal:  Front Pediatr       Date:  2022-08-23       Impact factor: 3.569

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.